FDA Surgical Stapler Recalls: 19 Class I Actions and the Misfire-and-Fragmentation Record

Executive Summary

Surgical staplers are the rare Class I (lowest-regulatory-burden) device family that the FDA reclassified upward after the post-market data became too damaging to ignore. Our analysis of the complete FDA enforcement, recall, and MAUDE record for the surgical-stapler product-code family finds a device category whose harm record is both large and concentrated:

• 222 FDA enforcement actions match surgical-stapler devices, of which 19 are Class I — the classification reserved for situations where use may cause serious injury or death — and Ethicon Endo-Surgery is the recalling firm on 18 of those 19 Class I actions
• The root causes split between manufacturing quality and staple-formation mechanics: across all 222 actions, sterility and contamination failures lead (51), followed by staple malformation or incomplete firing (44), misfire or uncontrolled articulation (38), fire and thermal faults (19), and fragmentation or breakage (13)
• The MAUDE adverse-event record is large and rising: 31,219 device reports under the stapler family product codes, including 280 death reports and 6,972 injury reports, with annual volume climbing from 760 reports in 2022 to 2,541 in 2024 and 1,703 in 2025
• A small group of manufacturers carries nearly the entire footprint: in MAUDE, Ethicon Endo-Surgery, Teleflex (Weck skin staplers), and United States Surgical (now part of Medtronic) account for the dominant share; in Class II enforcement, Covidien/Medtronic and Intuitive Surgical lead

For quality, regulatory, and surgical-supply-chain teams, the pattern is specific: the most serious stapler recalls are a jaw-component and firing-stroke integrity problem concentrated in one manufacturer, while the much larger Class II record is a sterility and process-control problem spread across the consolidated Covidien/Medtronic and Intuitive installed bases.

Why Surgical Staplers Were Reclassified Upward

Most device reclassifications move a product down a risk class to reduce regulatory burden. Surgical staplers went the other way. In March 2019, the FDA issued a Letter to Health Care Providers reporting that it had received more than 41,000 medical device reports for surgical staplers and staples for internal use since 2011, including 366 patient deaths (FDA, 2019). That letter followed reporting by Kaiser Health News that revealed many stapler malfunction reports had been routed to a non-public "alternative summary reporting" database rather than the public MAUDE system (AHA, 2019).

Within weeks, the FDA proposed reclassifying internal-use surgical staplers from Class I to Class II, which would subject them to premarket notification (510(k)) review and mandatory special controls for the first time (FDA, 2019). The final reclassification order issued in October 2021 (Federal Register, 2021).

The reporting discrepancy matters for anyone reading the historical data. The Kaiser Health News investigation found that more than 56,000 additional stapler malfunction and injury reports from 2011 through 2018 had been filed into a non-public "alternative summary reporting" database rather than MAUDE — more reports hidden than were public at the time (KFF Health News, 2019). Medtronic (which owns Covidien, the market leader) used the reporting exemption through July 2017, after which public stapler reports surged; Ethicon stated it had not used the exemption (KFF Health News, 2019). The sharp rise in public MAUDE stapler counts after 2019 reflects this reporting moving back into public view, not necessarily a sudden increase in real-world events. The product code at the center of the action is GAG — Stapler, Surgical, under 21 CFR 878.4740 — referenced by name in the FDA's labeling guidance (FDA guidance).

This analysis covers the stapler product-code family:

The general surgical stapler (GAG) is the focal product code; the skin stapler (QQS) and staple-line reinforcement meshes are included to capture the full device family.

Data Source and Method

• Sources: FDA device enforcement report database (reason-for-recall text and Class I/II/III classification), FDA Medical Device Recall database (recall initiation records by product code), and the FDA MAUDE adverse-event database (manufacturer and user-facility device reports by product code)
• Analysis sample: 222 enforcement-report records whose product description and reason-for-recall text match surgical-stapler devices; 31,219 MAUDE device reports filed under the five stapler-family product codes above; 63 510(k) clearances under the same codes
• Run date: 2026-06-14
• Method: All counts were computed by MedDeviceGuide from the public FDA enforcement, recall, and MAUDE extracts. Enforcement records do not carry a populated product-code field, so stapler records were identified by text matching of the device description and reason-for-recall fields against surgical-stapler terminology; firm names are reproduced as recorded by FDA. Root-cause themes were tallied from reason-for-recall text and are not mutually exclusive (a single action can match more than one theme).

The Enforcement Footprint

Across the 222 surgical-stapler enforcement actions, the classification split is heavily weighted toward Class II, with a meaningful Class I core:

The Class II record is broad and reflects the consolidated installed base. By recalling firm (as recorded by FDA), the firms appearing most often across the full enforcement record are Covidien/Medtronic (appearing under several legal entities — Covidien LP, Covidien LLC, Covidien Medtronic), Intuitive Surgical, and Ethicon Endo-Surgery, with W. L. Gore (staple-line reinforcement) also prominent.

Class I: An Ethicon-Dominated Record

The most striking finding in the stapler enforcement data is how concentrated the Class I actions are. Of the 19 Class I surgical-stapler enforcement actions, 18 list Ethicon Endo-Surgery Inc. as the recalling firm — with the remaining one attributed to Intuitive Surgical. No other manufacturer appears in the Class I stapler record over the period covered.

The Ethicon Class I reasons fall into two mechanical-failure modes:

• Insufficient firing stroke — "the staplers may have an insufficient firing stroke to break the washer and completely form staples," the reason text repeated across multiple circular-stapler actions, describing the 2019 Curved Intraluminal and EEA stapler recalls that prompted the FDA's broader safety review
• Out-of-specification jaw/anvil component — "the staplers may contain an out of specification anvil component within the jaw of the device. This condition may lead to malformation," describing malformed-staple risk from a component-tolerance defect

These map directly to the FDA's 2019 finding that the most commonly reported stapler problems were "opening of the staple line or malformation of staples, misfiring, difficulty in firing, failure of the stapler to fire the staple, and misapplied staples" (FDA, 2019). The clinical consequences the agency cited — bleeding, sepsis, fistula formation, tearing of internal tissues and organs, anastomotic leaks, increased risk of cancer recurrence, and death — are the exact harms that make these Class I rather than Class II actions.

Root Causes: Quality, Mechanics, and Fire

Tallying reason-for-recall text across all 222 enforcement actions produces a hierarchy that separates manufacturing-quality failures from device-mechanics failures:

Two themes deserve emphasis. The sterility-and-contamination bucket (51 actions) is the single largest and reflects process-control and packaging failures — "devices were shipped unsterilized" is a recurring reason statement. The mechanics bucket (malformation, misfire, and fragmentation combined: 44 + 38 + 13 = 95 actions) is where the patient-harm risk concentrates, because malformed or fragmented staples create anastomotic leaks and retained-foreign-object events that may not be detected until days after surgery. The fragmentation and device-fragment signals in particular appear in Intuitive Surgical's da Vinci-integrated stapling actions, where "staple deployment failure and device fragment generation" is the cited reason.

The MAUDE Record: 31,000 Reports and Rising

The MAUDE adverse-event database tells a complementary story. Under the five stapler-family product codes, we count 31,219 device reports, including 280 death reports, 6,972 injury reports, and 23,700 malfunction reports.

Annual report volume has climbed sharply in recent years, reflecting both the move of previously hidden summary reports into the public MAUDE system after 2019 and continued real-world reporting:

The brand-level distribution confirms the firm concentration seen in the enforcement data:

By manufacturer, Ethicon Endo-Surgery (4,858 reports), Teleflex (3,925 — the Weck skin-stapler line), and United States Surgical Corporation (3,806 — now within Medtronic) carry the largest MAUDE footprints. The same corporate names — Ethicon, Covidien/Medtronic (parent of US Surgical and Covidien), and the robotic-stapling entrants — dominate both the enforcement and the MAUDE records, which is what concentration across an installed base looks like in post-market data.

The 510(k) Entry Record

Despite the post-market burden, new stapler clearances continue. We count 63 510(k) clearances under the stapler family codes, overwhelmingly through the Traditional pathway (57 Traditional, 6 Special). The applicant field is concentrated in the same firms:

Clearance activity has been modest but steady in recent years — three in 2022, five in 2023, three in 2024, two in 2025, and one in the first half of 2026 — reflecting a mature, consolidated market with few new entrants. The combination of a concentrated clearance record and a concentrated recall record means that stapler post-market risk is effectively the post-market risk of a handful of legacy platforms.

The 2025 Ethicon Lockout Correction

The most recent significant stapler safety action fits the mechanical-failure pattern. In April 2025, Ethicon issued an Urgent Medical Device Correction for Endopath Echelon disposable stapler cartridges after an increase in reports of inadvertent instrument lockout during surgical procedures — the risk being that the user could not remove the locked device from tissue, with potential harms including surgical delay, bleeding, life-threatening hemorrhagic shock, and conversion to open surgery. The FDA placed the action in its Class I database; approximately 678,526 affected products were in commerce (MedTech Dive, 2025; FDA, 2025). The action was linked to at least one death. It is the clearest recent illustration that the firing-sequence integrity problem the FDA identified in 2019 has not been fully closed.

What This Means for Quality, Regulatory, and Supply-Chain Teams

The data supports four practical takeaways:

1. Separate the Class I risk from the Class II noise. Benchmarking against the full 222-action record understates the specific harm risk; the Class I record is overwhelmingly an Ethicon firing-stroke and jaw-component problem, and any post-market surveillance program covering staplers should weight that lineage accordingly.
2. Treat sterility and process control as the volume driver. The largest single root-cause bucket is contamination and unsterilized-shipment failures — a manufacturing-quality and packaging-process problem addressable through standard 21 CFR 820 process controls, not a device-design problem.
3. Watch the mechanics-to-harm pathway. Malformation, misfire, and fragmentation are the themes most likely to generate anastomotic leaks and retained-fragment events; these are the failure modes that escalate to death and injury reports in MAUDE and to Class I classification in enforcement.
4. Read the consolidated installed base as the recall base. Because Covidien, US Surgical, and Davis & Geck records now sit inside Medtronic and other successors, and Ethicon sits inside Johnson & Johnson, a health system's effective stapler recall exposure is concentrated in two or three supplier relationships.

Surgical staplers are now Class II devices precisely because their post-market record demanded special controls. The public data — 222 enforcement actions, 19 of them Class I and 18 of those Ethicon, and 31,000 MAUDE reports — is the evidence base that reclassification was built on, and it remains the benchmark against which current stapler safety performance should be measured.

Data sources: FDA device enforcement report database, FDA Medical Device Recall database, and FDA MAUDE adverse-event database; analysis by MedDeviceGuide, run date 2026-06-14. Root-cause themes are derived from FDA reason-for-recall text and are not mutually exclusive. This article is educational and is not regulatory, quality-system, or clinical advice for a specific product.